Correction: Veloxis Pharmaceuticals Announces Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
143
Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018

Company Release no. 12/2018

To:  Nasdaq Copenhagen A/S 

Copenhagen, Denmark, 16 May 2018

Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018

Correction: In the company release titled “Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018” issued 14-May-2018, the Outlook for 2018 section should read “Veloxis maintains its 2018 outlook of revenues to be in the range of USD 32 – 40 million and operating loss before accounting for stock compensation in the range of USD 6 – 12 million.”  The original release erroneously stated that operating loss before accounting for stock compensation would be in the range of USD 4 – 10 million.

The complete, corrected release follows:

Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the First Three Months of 2018.  This company release should be read in conjunction with Veloxis's full Interim Report for the First Three Months of 2018, which is attached to this release and also available on Veloxis's website at www.veloxis.com .

Highlights

  • Product revenue for Q1 2018 was tUSD 7,265 an increase of 142% compared to the same period last year. 
  • U.S. revenue increased 150% to tUSD 6,418. 
  • EU revenue increased 96% to tUSD 841. 
  • Over 79% of U.S. transplant centers have utilized Envarsus XR® since launch.  
  • Veloxis obtained USD 60 million of capital from funds managed by Athyrium Capital Management, LP, a leading healthcare-focused investment firm. 
  • Veloxis submitted a supplemental New Drug Application to the U.S. FDA seeking a new indication for Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants. 
  • Morten Marott joined Veloxis as Chief Financial Officer. 
  • Veloxis reported a net loss of tUSD 4,030 for the first quarter of 2018 compared to a net loss of tUSD 5,891 for the same period in 2017.  The reported operating net loss is in line with expectations.

In connection with the financial report, Veloxis’s CEO, Craig Collard said:    

“2018 is off to a fantastic start with the filing of our sNDA for the de novo indication, the closing of our financing with Athyrium, the hiring of our new CFO, Morten Marott, and, most importantly, the continued growth of Envarsus.”

  

Outlook for 2018  

Veloxis maintains its 2018 outlook of revenues to be in the range of USD 32 – 40 million and operating loss before accounting for stock compensation in the range of USD 6 – 12 million.

Conference Call      

A conference call will be held tomorrow, 15 May 2018 at 4:00 PM CET (Denmark); 10:00 AM EST (New York). 

To access the live conference call, please dial one of the following numbers: 

Confirmation Code: 8366822 

U.S.: +1 929 477 0275 

DK: +45 35 15 80 50

Following the conference call, a recording will be available on the Company’s website: http://www.veloxis.com .

For more information, please contact:

Craig A. Collard

President & CEO

Phone:  +1 919 591 3090

Email:  cac@veloxis.com

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailablity of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties.  Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com .

Attachment  

Correction - Release 12 2018 - Veloxis Q1 2018 Interim Report

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 18

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 54

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 39

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 11

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 28

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 71

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 84

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 55

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 116

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 43

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading

Top 5 Most Recently Viewed Articles

Lifeboat Market Growth Drivers & Future Projections 2024-2033

Updated Category News Views 82

Lifeboat Market Growth Drivers & Future Projections Recent market analysis indicates that the global lifeboat market is on a trajectory of significant growth, expected to expand from a valuation of $311.0 million in 2023 to approximately $416.3 million by 2033, at a compound annual growth rate (CAGR) of 3.2%. This upward trend is primarily driven by stringent maritime...

Continue Reading
Envista Holdings Corp: An Insight Into Market Trends

Updated Category News Views 198

Understanding Envista Holdings Corp's Market Dynamics Envista Holdings Corp (NYSE: NVST) has witnessed notable movements in its short interest percentage recently. The figure has seen a decline of 11.19% from the last available report, indicating a shift in market sentiment. Currently, there are approximately 9.10 million shares sold short, representing 6.67% of the...

Continue Reading
Breakthrough Medical Device Addresses Lipohypertrophy in Diabetes

Updated Category News Views 544

Revolutionizing Diabetes Treatment with Embrace Patch Recent clinical trials have shed light on the embrace Active Site Care compression patch, a pioneering medical device that has demonstrated its efficacy in treating lipohypertrophy (LH) in individuals using insulin for diabetes management. This breakthrough reveals how comprehensive care and innovative technology can...

Continue Reading
Investors' Perspectives on Carpenter Technology Corp's Stock Trends

Updated Category News Views 184

Understanding Carpenter Technology Corp's Short Interest Carpenter Technology Corp (NYSE: CRS) has seen a significant shift in its short interest as a percentage of float, which has decreased by 18.6% since its last report. According to the latest data from exchanges, the current short interest stands at approximately 2.54 million shares sold short, equating to around...

Continue Reading
Exploring Palantir's Future: Sustainable Growth or a Bubble?

Updated Category News Views 416

Palantir Technologies Inc: A Deep Dive into Its Future Palantir Technologies Inc (NASDAQ: PLTR) is attracting considerable attention from investors and industry watchers alike. Renowned for its cutting-edge AI-driven software solutions, Palantir is at the forefront of transforming both defense and enterprise sectors. Following a remarkable surge of 400% in stock value...

Continue Reading